Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - vinblastine sulfate - solution for inj/inf - 1 mg/ml - vinca alkaloids and analogues

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - vinblastine sulfate - solution for injection/infusion - 1 milligram(s)/millilitre - vinca alkaloids and analogues; vinblastine

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cipla malaysia sdn bhd - bleomycin sulphate -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kyowa kirin ltd - bleomycin sulfate - powder for solution for injection - 15000unit

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - bleomycin sulfate 15000 [iu] equivalent to to 10 mg. - powder for injection - 15000 iu - active: bleomycin sulfate 15000 [iu] equivalent to to 10 mg.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - powder and solvent for solution for injection - bleomycin sulfate 15000 i.u. - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

lundbeck limited - bleomycin sulfate - 15 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

lundbeck limited - bleomycin sulfate - pdr for soln inj/inf - 15 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - bleomycin sulfate, quantity: 15 iu - injection, powder for - excipient ingredients: sodium hydroxide; sulfuric acid - managment of the following neoplasms either as a single agent or in combination with other chemotherapeutic agents: squamous cell carcinoma, lymphomas, testicular carcinoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sulfuric acid; mannitol; water for injections; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma